GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (FRA:7NS0) » Definitions » Valuation Rank

Palisade Bio (FRA:7NS0) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Palisade Bio Valuation Rank Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisade Bio (FRA:7NS0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (FRA:7NS0) » Definitions » Valuation Rank
Comparable Companies
NAVB TCON WINT SNGX XCUR RGBP TSOI FRTX HOTH THER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
PALI:USA
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Website
https://www.palisadebio.com
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.